PD-1/PD-L1抑制剂为基础的肿瘤免疫治疗疗效标志物的研究进展

Research progress of tumor immunotherapy efficacy markers based on PD-1/PD-L1 inhibitors

目前,肿瘤的治疗手段多种多样,具体的治疗方案根据肿瘤分期、性质及患者自身状态而定。而以PD-1/PD-L1抑制剂为基础的免疫治疗疗法引领肿瘤治疗进入了新时代,在多种实体瘤中都取得了巨大成功。临床实践却发现,并非所有的患者都能从免疫治疗中获益,甚至免疫治疗会导致患者病情出现爆发性进展或假性进展。因此,为实现更精准的治疗,减少患者经济损失,提高免疫抑制剂的有效率,探寻合适的疗效预测标志物来筛选可受益的患者成为了临床重要的研究热点和迫切需求。免疫疗法拥有巨大的应用潜力,筛选其疗效预测标志物对预后分层、辅助诊断、药物选择等方面具有重要的意义。为进一步指导临床,本文就PD-1/PD-L1抑制剂的疗效标志物作出系统综述。

At present,there are many treatments for tumors.The specific treatment plan depends on the stage,nature and state of the tumor.The immunotherapy based on the PD-1/PD-L1 inhibitors has led to a new era of tumor therapy,and has achieved great success in many solid tumors.Clinical practice has found that not all patients benefit from immunotherapy,and even immunotherapy can lead to explosive progression or false progression.Therefore,in order to achieve more accurate treatment,reduce the economic loss of patients,improve the effective rate of immunosuppressants,explore the appropriate efficacy prediction markers to screen the beneficial patients has become an important clinical research focus and urgent needs.Immunotherapy has great potential for application,and screening its prognostic markers is of great significance prognosis stratification,auxiliary diagnosis,drug selection and so on.For further guidance,this paper reviews the efficacy markers of PD-1/PD-L1 inhibitors.